Key Points
- Director Keith Meister bought 165,000 GeneDx shares on May 13 at an average price of $39.09, spending about $6.45 million. The purchase lifted his ownership to 4,598,297 shares, a 3.72% increase.
- GeneDx recently disappointed on earnings, reporting a wider-than-expected loss of $0.28 per share and revenue of $102.25 million, both below analyst estimates. The company also has a negative net margin and analysts expect a full-year loss.
- Despite volatility, Wall Street remains cautiously positive: the stock still carries a “Moderate Buy” consensus, though several analysts have cut price targets. At the same time, institutional ownership remains high at 61.72%, and legal investigations into potential shareholder claims have emerged after the weak quarter.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) Director Keith Meister bought 46,273 shares of the business's stock in a transaction on Friday, May 15th. The stock was bought at an average price of $38.91 per share, for a total transaction of $1,800,482.43. Following the transaction, the director directly owned 4,784,570 shares of the company's stock, valued at approximately $186,167,618.70. This represents a 0.98% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
GeneDx Stock Performance
Shares of GeneDx stock opened at $40.75 on Friday. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The firm has a market capitalization of $1.21 billion, a P/E ratio of -15.21 and a beta of 2.06. The company's 50 day moving average price is $64.01 and its two-hundred day moving average price is $102.00.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The company had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. During the same quarter in the prior year, the business earned ($0.23) EPS. On average, equities analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.
Institutional Investors Weigh In On GeneDx
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp increased its stake in GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock valued at $25,000 after purchasing an additional 186 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in GeneDx in the fourth quarter valued at $27,000. Fifth Third Bancorp bought a new stake in GeneDx in the first quarter valued at $31,000. Quarry LP increased its stake in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company's stock valued at $32,000 after purchasing an additional 209 shares in the last quarter. Finally, Ramirez Asset Management Inc. bought a new stake in GeneDx in the fourth quarter valued at $33,000. 61.72% of the stock is owned by institutional investors.
Key Stories Impacting GeneDx
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: Director Keith A. Meister kept buying shares, including 165,000 shares on May 13, 140,000 shares on May 14, and 46,273 shares on May 15, signaling strong insider confidence in GeneDx’s outlook and helping support the stock. Insider trade filing
- Neutral Sentiment: GeneDx received an average brokerage recommendation of “Moderate Buy,” suggesting Wall Street still sees upside despite the recent volatility. Brokerage recommendation article
- Negative Sentiment: A legal update from Pomerantz LLP said it is investigating claims on behalf of GeneDx investors, adding overhang from possible shareholder litigation after the company’s recent results. Pomerantz investigation article
- Negative Sentiment: Another law firm, Levi & Korsinsky, announced a securities investigation tied to GeneDx’s Q1 revenue miss and reduced full-year guidance, reinforcing concerns that the post-earnings selloff may not be over. Levi & Korsinsky investigation article
- Negative Sentiment: An analyst note cut GeneDx’s price target sharply to $98.94, highlighting a more cautious view after the company’s disappointing quarter. Price target cut article
Analyst Ratings Changes
A number of brokerages have recently commented on WGS. Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the stock a "buy" rating in a report on Tuesday, May 5th. Wells Fargo & Company reiterated an "overweight" rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Guggenheim cut their price target on shares of GeneDx from $100.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, May 5th. Zacks Research lowered shares of GeneDx from a "strong-buy" rating to a "hold" rating in a report on Friday, April 24th. Finally, Jefferies Financial Group set a $150.00 price target on shares of GeneDx in a report on Monday, February 23rd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.43.
View Our Latest Research Report on GeneDx
About GeneDx
(
Get Free Report)
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
